2A Pharma’s B-cell epitope vaccine candidate, AAVLP-IgE, has in laboratory tests with non-human primates been shown to be effective at inducing anti-IgE autoantibodies. This gives the potential for a vaccine with similar benefits to approved anti‐human immunoglobulin E (IgE) antibody treatments of, for example, asthma, nut allergy etc. Currently, the potential of a bivalent AAVLP-IgE vaccine is being investigated.
Back
Biopharmaceutical company